EyePoint Pharmaceuticals, Inc.EYPT
| Jun 30,
2012 | Jun 30,
2013 | Jun 30,
2014 | Jun 30,
2015 | Jun 30,
2016 | Jun 30,
2017 | Jun 30,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net loss | - | - | - | - | - | - | -53 | -57 | -45 | -58 | -102 |
|---|
| Amortization of intangible assets | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 |
|---|
| Impairment of intangible assets | 15 | - | - | - | - | - | - | - | - | - | 21 |
|---|
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 396,000 |
|---|
| Amortization of debt discount and premium and discount on available-for-sale marketable securities | - | - | - | - | - | - | - | - | - | - | -1 |
|---|
| Paid-in-Kind Interest | - | - | - | - | - | - | - | 1 | 1 | - | - |
|---|
| Loss (gain) on extinguishment of debt | - | - | - | - | - | - | - | -4 | -1 | 2 | -2 |
|---|
| Inventory Write-down | - | - | - | - | - | - | - | - | - | 1 | 2 |
|---|
| Stock-based compensation | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 5 | 6 | 7 | 14 |
|---|
| Accounts receivable and other current assets | - | - | - | - | - | - | - | 15 | -5 | 11 | 3 |
|---|
| Inventory | - | - | - | - | - | - | - | 2 | 3 | -1 | 1 |
|---|
| Accounts payable and accrued expenses | - | - | - | - | - | - | - | 5 | 2 | 8 | 1 |
|---|
| Right-of-use assets and operating lease liabilities | - | - | - | - | - | - | - | 0 | 0 | -0 | 0 |
|---|
| Deferred revenue | - | - | - | - | - | - | - | -0 | 17 | -1 | -1 |
|---|
| Net cash used in operating activities | -9 | -9 | - | - | - | - | -22 | -57 | -14 | -50 | -65 |
|---|
| Purchases of marketable securities | 15 | 8 | 3 | 10 | 18 | - | - | - | - | 33 | 139 |
|---|
| Sales and maturities of marketable securities | 15 | 14 | - | - | - | 19 | - | - | - | - | 124 |
|---|
| Purchases of property and equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
|---|
| Net cash used in investing activities | 1 | 6 | - | - | - | - | -17 | -0 | -0 | -33 | -17 |
|---|
| Proceeds From Issuance Of Stock And Pre Funded Warrants Net Of Issuance Costs | - | - | - | - | - | - | - | - | - | 217 | - |
|---|
| Proceeds from issuance of long-term debt | - | - | - | - | - | - | 20 | 50 | - | - | 30 |
|---|
| Payment of equity and debt issue costs | - | - | - | - | - | - | - | - | - | - | 1 |
|---|
| Payment of long-term debt | - | - | - | - | - | - | - | 20 | 14 | - | 38 |
|---|
| Payment of extinguishment of debt costs | - | - | - | - | - | - | - | 3 | 1 | - | 2 |
|---|
| Proceeds from Lines of Credit | - | - | - | - | - | - | - | - | - | - | 44 |
|---|
| Repayment under revolving facility | - | - | - | - | - | - | - | - | - | - | 33 |
|---|
| Net settlement of stock units to satisfy statutory tax withholding | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Proceeds from Stock Options Exercised | - | - | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
|---|
| Principal payments on finance lease obligations | - | - | - | - | - | - | - | - | 0 | 0 | 137,000 |
|---|
| Net cash (used in) provided by financing activities | 0 | 5 | - | - | - | - | 61 | 34 | 37 | 217 | -1 |
|---|
| Effect of foreign exchange rate changes on cash and cash equivalents | - | - | - | - | - | - | 0 | 0 | - | - | - |
|---|
| Net (decrease) increase in cash, cash equivalents and restricted cash | - | - | - | - | - | - | 22 | -23 | 23 | 134 | -83 |
|---|
| Cash interest paid | - | - | - | - | - | - | 0 | 5 | 6 | 5 | 3 |
|---|
| Stock issuance costs | - | - | - | - | - | - | - | - | - | 0 | - |
|---|
| Debt Instrument Exit Fee | - | - | - | - | - | - | - | 3 | 0 | - | 1 |
|---|
| Payments forgiven under paycheck protection program loan | - | - | - | - | - | - | - | - | - | 2 | - |
|---|